Looks like Aduhelm controversial approval is causing problems for Biogen.
Biogen Limits Alzheimer’s Drug Use With Updated Label (bloombergquint.com)
FDA defends approval of controversial Alzheimer's drug (medicalxpress.com)
"In granting approval, the FDA ran counter to its own advisory committee of experts, which voted 10 out of 11 against approving Aduhelm, as well as other Alzheimer's experts that included some of the doctors who ran the drug's clinical trials in hospitals across the nation"
3 members of that panel resigned after the approval...
I can't understand how a panel of experts voted 10-1 against and it got through.
Maybe Aduhelm's pain is our GAIN??
DYOR
Looks like Aduhelm controversial approval is causing problems...
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $1.629K | 543K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 97966 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 137498623 | 32 |
View Market Depth
| Last trade - 09.59am 17/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |